| |
|
CritiTech Announces
Additions to the Board of Directors and the Scientific Advisory
Board
August 24, 2010
FOR IMMEDIATE RELEASE
Lawrence, Kansas -- Sam Campbell, Chairman
and President of CritiTech, Inc. announced today the addition
of Dr. Francois Sauer, M.D., MBA to its Board of Directors
and Dr. Michael Baltezor, Ph.D. to its Scientific Advisory
Board. “We welcome the addition of these two very experienced
and accomplished gentlemen to our team. I am confident that
they will play an important role in the future success of
CritiTech” said Campbell.
Dr. Sauer received his M.D. degree with honors
from the University of Mexico, UNAM, his MBA from IPADE (Harvard
Business School program in Mexico City), and a MS Systems
Analysis from the Spanish-American University, Mexico City.
Presently, Dr. Sauer is the CEO of Trans Am Group (TAG). TAG
promotes importing and exporting between Mexico, Canada, and
the United States with a focus on health services and logistics.
Prior to that, he was the CEO of BCEC, a business incubator,
and the CEO of Cerner International, maker of IT products
for health industry applications with presence in Australia,
Singapore, Malaysia, Saudi Arabia, and Europe. Dr. Sauer has
served in numerous other business and professional leadership
positions. He was a Founding member of the National Athenaeum
of Arts, Letters, Sciences and Technology in Mexico and has
published peer-reviewed articles in journals such as: British
Medical Journal, Lancet, Military Medicine, and Nature Medicine.
“Dr. Sauer will dynamically impact our board and expand
the international presence of our company” Campbell
said.
Dr. Michael Baltezor received his Ph. D. in
Pharmaceutics and Pharmaceutical Chemistry from the University
of Kansas in 1977. He has been involved in the development
of pharmaceutical and medicinal products for over 30 years
with Sandoz Pharmaceuticals, Marion Laboratories (and subsequent
companies) and in the contract services business with Quintiles.
He also served as the Vice President of R&D for CareFusion,
Inc. Most recently, Dr. Baltezor became the Director of the
Biotechnology Innovation and Optimization Center at the University
of Kansas. His experience has included a spectrum of ethical
and OTC drugs and devices including traditional oral solid
and liquid dosage forms, topical products and injectable parenteral
products. Dr. Baltezor’s primary areas of expertise
are in pharmaceutics, physical chemistry and analytical chemistry
with a focus on novel drug delivery and the resolution of
drug solubilization and stabilization. Dr. Charles Decedue,
Chairman of CritiTech’s Scientific Advisory Board, said
“Dr. Baltezor is a great addition to CritiTech’s
Scientific Advisory Board. His vast experience in both large
pharmaceutical companies and highly competitive contract research
organizations will have a large impact on CritiTech’s
R&D efforts”.
CritiTech provides critical drug delivery and development
technology for the pharmaceutical industry. CritiTech produces
fine-particle pharmaceuticals including nanoparticle pharmaceuticals
using patented technologies developed at the University of
Kansas. The processes use compressed carbon dioxide as the
processing medium to produce residue-free and uniform drug
microparticles and coatings.
The pharmaceutical industry has exhibited substantial
interest in the processes that produce improved formulations
using nanoparticulate drugs. CritiTech has used its proprietary
technology to coat medicinal agents either on small particle
drugs for improved drug delivery or as a thin film on implantable
medical devices such as cardiac stents. CritiTech’s
first oncology drug, Nanotax®, for the treatment of ovarian
cancer, is in Phase I human clinical trials. CritiTech plans
to have its second oncology drug, Nanothecin™, for the
treatment of colorectal cancer, in Phase I human trials early
next year.
|
